Isapejuwe
Agbe ti molecular ti agbedemeji yii jẹ C13H10c10cl3, ati iwuwo ti molecular rẹ 307.755. Eto igbekun pipe rẹ jẹ ki awọn iṣelọpọ daradara ati giga ti tefacitinib. Therefore, the tofacitinib intermediate 1,4-chloro-7-p-toluenesulfonyl-7H pyrrolo[2,3-d]pyrimidine is an important component in the pharmaceutical industry to provide effective treatment for autoimmune diseases.
Awọn ọja wa ti ṣelọpọ lilo awọn ilana-aworan-aworan aworan lati rii daju didara ti o ga julọ ati aitasera. A ni oye pataki ti nini ajọṣepọ igbẹkẹle ati funfun alade ni iṣelọpọ elegbogi, eyiti a fi pinnu lati ṣetọju awọn iṣedede iṣelọpọ lakoko ilana iṣelọpọ wa. Wa Ramocitinabaniba agbedemeji 1,4-Chloro-7-Pyruensulconyl-7h Pyruensulconyl-7h Pyrimidine [2,3-D] gba purrimidine [2,3-D] gba purrimidine [2,3-d] lati ni igboya ninu igbẹkẹle ninu igbẹkẹle ti tetacacitinib.
Yan Wa
JDK ni o ni awọn ohun elo iṣelọpọ akọkọ-kilasi akọkọ ati awọn ohun elo iṣakoso didara, eyiti o ṣe idaniloju ipese iduroṣinṣin ti awọn ibatan pẹlu awọn ibi. Ẹgbẹ ọjọgbọn ti o daju R & D ti ọja naa. Lodi si awọn mejeeji, a n wadi fun CMO & CDMO ni ọja ile ati ilu okeere.
